Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate vs. Risperidone in ADHD and Disruptive Disorders
NCT02063945Phase 4Terminated
- Sponsor
- Sheba Medical Center
- Start
- Feb 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in attention deficit hyperactivity disorder (ADHD), oppositional defiant disorder (ODD) and conduct disorder (CD) comparing Methylphenidate with Risperidone (2 arms). Primary endpoint: Change from baseline of aggressive behaviors at 8 weeks. Started Feb 2017; status: terminated.
02
Drugs
methylphenidaterisperidone
03
Conditions
attention deficit hyperactivity disorder (ADHD)oppositional defiant disorder (ODD)conduct disorder (CD)
Beyond the preview
Go deeper on NCT02063945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02063945.